120 related articles for article (PubMed ID: 23415961)
21. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors.
Wehrli BM; Huang W; De Crombrugghe B; Ayala AG; Czerniak B
Hum Pathol; 2003 Mar; 34(3):263-9. PubMed ID: 12673561
[TBL] [Abstract][Full Text] [Related]
22. Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone.
Masi L; Malentacchi C; Campanacci D; Franchi A
Virchows Arch; 2002 May; 440(5):491-7. PubMed ID: 12021923
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of TGFβ signaling and its implications in anticancer treatments.
Calone I; Souchelnytskyi S
Exp Oncol; 2012; 34(1):9-16. PubMed ID: 22453142
[TBL] [Abstract][Full Text] [Related]
24. PTHrP and Bcl-2: essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors.
Amling M; Pösl M; Hentz MW; Priemel M; Delling G
Verh Dtsch Ges Pathol; 1998; 82():160-9. PubMed ID: 10095428
[TBL] [Abstract][Full Text] [Related]
25. Mesenchymal chondrosarcoma: an immunohistochemical study of 10 cases examining prognostic significance of proliferative activity and cellular differentiation.
Nussbeck W; Neureiter D; Söder S; Inwards C; Aigner T
Pathology; 2004 Jun; 36(3):230-3. PubMed ID: 15203726
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
27. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells.
Kim DW; Seo SW; Cho SK; Chang SS; Lee HW; Lee SE; Block JA; Hei TK; Lee FY
J Orthop Res; 2007 Jun; 25(6):820-8. PubMed ID: 17343283
[TBL] [Abstract][Full Text] [Related]
28. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
Wang G; Zhan Y; Wang H; Li W
Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
[TBL] [Abstract][Full Text] [Related]
29. FKBP38-Bcl-2 interaction: a novel link to chemoresistance.
Choi BH; Yoon HS
Curr Opin Pharmacol; 2011 Aug; 11(4):354-9. PubMed ID: 21571591
[TBL] [Abstract][Full Text] [Related]
30. Bcl-xL is phosphorylated in malignant cells following microtubule disruption.
Poruchynsky MS; Wang EE; Rudin CM; Blagosklonny MV; Fojo T
Cancer Res; 1998 Aug; 58(15):3331-8. PubMed ID: 9699663
[TBL] [Abstract][Full Text] [Related]
31. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
[TBL] [Abstract][Full Text] [Related]
32. The oncogene LRF is a survival factor in chondrosarcoma and contributes to tumor malignancy and drug resistance.
Kumari R; Li H; Haudenschild DR; Fierro F; Carlson CS; Overn P; Gupta L; Gupta K; Nolta J; Yik JH; Di Cesare PE
Carcinogenesis; 2012 Nov; 33(11):2076-83. PubMed ID: 22847180
[TBL] [Abstract][Full Text] [Related]
33. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
34. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
35. Mesenchymal chondrosarcoma: a clinicopathologic and flow cytometric study of 13 cases presenting in the central nervous system.
Rushing EJ; Armonda RA; Ansari Q; Mena H
Cancer; 1996 May; 77(9):1884-91. PubMed ID: 8646689
[TBL] [Abstract][Full Text] [Related]
36. Bcl-2 gene silencing in pediatric epithelial liver tumors.
Warmann SW; Frank H; Heitmann H; Ruck P; Herberts T; Seitz G; Fuchs J
J Surg Res; 2008 Jan; 144(1):43-8. PubMed ID: 17574594
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas.
Grifone TJ; Haupt HM; Podolski V; Brooks JJ
Int J Surg Pathol; 2008 Jan; 16(1):31-7. PubMed ID: 18203781
[TBL] [Abstract][Full Text] [Related]
38. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
39. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
40. Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis.
Amer KM; Munn M; Congiusta D; Abraham JA; Basu Mallick A
J Orthop Res; 2020 Feb; 38(2):311-319. PubMed ID: 31498474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
